John Bridgewater
Overview
Explore the profile of John Bridgewater including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
9936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan S, Rushbrook S, Kendall T, Zen Y, Albazaz R, Manoharan P, et al.
Gut
. 2024 Aug;
74(3):504-505.
PMID: 39160057
No abstract available.
2.
Harding J, Fan J, Oh D, Choi H, Kim J, Chang H, et al.
Future Oncol
. 2024 Aug;
20(31):2319-2329.
PMID: 39114870
What Is This Summary About?: Researchers wanted to study whether the research drug zanidatamab could help people with a type of cancer called biliary tract cancer. In some people, biliary...
3.
Oh D, Ikeda M, Lee C, Rojas C, Hsu C, Kim J, et al.
Hepatology
. 2024 Jun;
81(3):823-836.
PMID: 38875119
Background And Aims: We compared the safety and efficacy of bintrafusp alfa (BA) in combination with gemcitabine+cisplatin (GemCis), to those of GemCis alone, in patients with biliary tract cancer. Approach...
4.
Gogenur M, Rosen A, Iveson T, Kerr R, Saunders M, Cassidy J, et al.
JAMA Surg
. 2024 Jun;
159(8):865-871.
PMID: 38865139
Importance: The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, with no consensus on the optimal...
5.
Lakatos E, Gunasri V, Zapata L, Househam J, Heide T, Trahearn N, et al.
bioRxiv
. 2024 Feb;
PMID: 38405882
Immune system control is a major hurdle that cancer evolution must circumvent. The relative timing and evolutionary dynamics of subclones that have escaped immune control remain incompletely characterized, and how...
6.
Mahmood U, Muhamad Faizul E, Howlett S, Amin Z, Hochhauser D, Shiu K, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398088
Background: Cholangiocarcinoma (CCA) is associated with poor outcomes and limited treatment options, leading to increased use of targeted therapies for its management. Here, we performed one of the largest single-centre...
7.
Nooijen L, van der Snee L, Ten Haaft B, Kazemier G, Klumpen H, Bridgewater J, et al.
HPB (Oxford)
. 2023 Oct;
26(2):179-187.
PMID: 37891150
Background: There is currently no evidence to support structured use of imaging or biomarkers during follow-up of patients after curative resection of biliary tract cancer (BTC). Besides, the influence of...
8.
Rushbrook S, Kendall T, Zen Y, Albazaz R, Manoharan P, Pereira S, et al.
Gut
. 2023 Sep;
73(1):16-46.
PMID: 37770126
These guidelines for the diagnosis and management of cholangiocarcinoma (CCA) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included a multidisciplinary team of experts...
9.
ORourke C, Salati M, Rae C, Carpino G, Leslie H, Pea A, et al.
Gut
. 2023 Sep;
73(3):496-508.
PMID: 37758326
Objective: Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict...
10.
Chambers P, Watson M, Bridgewater J, Forster M, Roylance R, Burgoyne R, et al.
Cancer Med
. 2023 Aug;
12(17):17856-17865.
PMID: 37610318
Background: In those receiving chemotherapy, renal and hepatic dysfunction can increase the risk of toxicity and should therefore be monitored. We aimed to develop a machine learning model to identify...